Steven Grant, M.D. - Publications

Affiliations: 
Virginia Commonwealth University, Richmond, VA, United States 
Area:
Pharmacology, Biochemistry
Website:
https://medschool.vcu.edu/expertise/detail.html?ID=845

122 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Dasmahapatra G, Nguyen TK, Dent P, Grant S. Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]. Leukemia Research. PMID 31079870 DOI: 10.1016/j.leukres.2019.03.002  0.56
2019 Zhou L, Zhang Y, Leng Y, Dai Y, Kmieciak M, Kramer L, Sharma K, Wang Y, Craun W, Grant S. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo. Journal of Hematology & Oncology. 12: 25. PMID 30845975 DOI: 10.1186/s13045-019-0713-x  0.72
2018 Nguyen T, Parker R, Zhang Y, Hawkins E, Kmieciak M, Craun W, Grant S. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. Bmc Cancer. 18: 1129. PMID 30445933 DOI: 10.1186/s12885-018-5018-x  0.6
2018 Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, ... ... Grant S, et al. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 18: 569-575.e1. PMID 30122201 DOI: 10.1016/j.clml.2018.05.023  0.6
2018 Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, Leverson JD, Sampath D, Ferreira-Gonzalez A, Grant S. Co-targeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Research. PMID 29559471 DOI: 10.1158/0008-5472.CAN-17-3024  0.6
2017 Zhou L, Zhang Y, Sampath D, Leverson J, Dai Y, Kmieciak M, Nguyen M, Orlowski RZ, Grant S. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. British Journal of Cancer. PMID 29241222 DOI: 10.1038/bjc.2017.432  0.72
2017 Zhang Y, Zhou L, Leng Y, Dai Y, Orlowski RZ, Grant S. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget. 8: 59476-59491. PMID 28938651 DOI: 10.18632/oncotarget.19761  0.72
2017 Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms. Oncotarget. PMID 28416758 DOI: 10.18632/oncotarget.15649  0.6
2017 Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, ... ... Grant S, et al. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leukemia & Lymphoma. 1-9. PMID 28103725 DOI: 10.1080/10428194.2016.1276287  0.6
2016 Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. PMID 27806331 DOI: 10.18632/oncotarget.12969  0.72
2016 Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. The Journal of Biological Chemistry. 291: 20823. PMID 27664064 DOI: 10.1074/jbc.A116.803444  0.56
2016 Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. Journal of Hematology & Oncology. 9: 73. PMID 27557643 DOI: 10.1186/s13045-016-0304-z  0.72
2016 Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S. Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway. The Journal of Biological Chemistry. 291: 17535. PMID 27543593 DOI: 10.1074/jbc.A109.095208  0.56
2016 Wan W, Pei XY, Grant S, Birch JB, Felthousen J, Dai Y, Fang HB, Tan M, Sun S. Nonlinear response surface in the study of interaction analysis of three combination drugs. Biometrical Journal. Biometrische Zeitschrift. PMID 27185067 DOI: 10.1002/bimj.201500021  0.72
2016 Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Rahmani M, Povirk L, Chalasani S, Berger AJ, Dai Y, ... Grant S, et al. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood. PMID 26851293 DOI: 10.1182/blood-2015-06-653717  0.72
2016 Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, ... ... Grant S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12: 1-222. PMID 26799652 DOI: 10.1080/15548627.2015.1100356  0.6
2015 Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica. PMID 26452980 DOI: 10.3324/haematol.2015.130351  0.72
2015 Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann MA, Xi L, Raffeld M, Zhao X, Wan W, ... ... Grant S, et al. A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446942 DOI: 10.1158/1078-0432.CCR-15-1076  0.72
2015 Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, ... ... Grant S, et al. Phase 1 Trial of Carfilzomib (PR-171) in Combination with Vorinostat (SAHA) in Patients with Relapsed or Refractory B-Cell Lymphomas. Leukemia & Lymphoma. 1-30. PMID 26284612 DOI: 10.3109/10428194.2015.1075019  0.72
2015 Sperlazza J, Rahmani M, Beckta J, Aust M, Hawkins E, Wang SZ, Zhu SZ, Podder S, Dumur C, Archer K, Grant S, Ginder GD. Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation. Blood. PMID 26265695 DOI: 10.1182/blood-2015-03-631606  0.44
2015 Grant S. ATRA and ATO team up against NPM1. Blood. 125: 3369-71. PMID 26022051 DOI: 10.1182/blood-2015-04-636217  0.72
2015 Yazbeck VY, Grant S. Romidepsin for the treatment of non-Hodgkin's lymphoma. Expert Opinion On Investigational Drugs. 24: 965-79. PMID 25936363 DOI: 10.1517/13543784.2015.1041586  0.72
2015 Fang HB, Chen X, Pei XY, Grant S, Tan M. Experimental design and statistical analysis for three-drug combination studies. Statistical Methods in Medical Research. PMID 25744107 DOI: 10.1177/0962280215574320  0.48
2015 Dai Y, Grant S. BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Autophagy. 11: 416-8. PMID 25700997 DOI: 10.1080/15548627.2014.998892  0.72
2015 Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells. Leukemia Research. 39: 65-71. PMID 25465126 DOI: 10.1016/j.leukres.2014.10.009  0.72
2015 Kiebala M, Skalska J, Casulo C, Brookes PS, Peterson DR, Hilchey SP, Dai Y, Grant S, Maggirwar SB, Bernstein SH. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Experimental Hematology. 43: 89-99. PMID 25448488 DOI: 10.1016/j.exphem.2014.10.004  0.72
2015 Hamed HA, Tavallai S, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. Journal of Cellular Physiology. 230: 131-9. PMID 24911215 DOI: 10.1002/jcp.24689  0.72
2014 Bose P, Batalo MS, Holkova B, Grant S. Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opinion On Pharmacotherapy. 15: 2443-59. PMID 25263936 DOI: 10.1517/14656566.2014.965142  0.72
2014 Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, ... ... Grant S, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5652-62. PMID 25248382 DOI: 10.1158/1078-0432.CCR-14-0805  0.6
2014 Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Molecular Cancer Therapeutics. 13: 2886-97. PMID 25239935 DOI: 10.1158/1535-7163.MCT-14-0220  0.72
2014 Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood. 124: 2687-97. PMID 25208888 DOI: 10.1182/blood-2014-03-564534  0.72
2014 Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. Plos One. 9: e103015. PMID 25181509 DOI: 10.1371/journal.pone.0103015  0.88
2014 Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, Dent P. Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. Molecular Cancer Therapeutics. 13: 2384-98. PMID 25103559 DOI: 10.1158/1535-7163.MCT-14-0172  0.72
2014 Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4849-60. PMID 25070836 DOI: 10.1158/1078-0432.CCR-14-0034  0.72
2014 Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant S. Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Molecular and Cellular Biology. 34: 3435-49. PMID 25002530 DOI: 10.1128/MCB.01383-13  0.72
2014 Bose P, Grant S. Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leukemia Research. 38: 862-5. PMID 24996975 DOI: 10.1016/j.leukres.2014.06.007  0.72
2014 Vachhani P, Bose P, Rahmani M, Grant S. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiological Genomics. 46: 448-56. PMID 24824212 DOI: 10.1152/physiolgenomics.00173.2013  0.72
2014 Grant S. Bortezomib resistance and MUC1 in myeloma. Blood. 123: 2910-2. PMID 24810626 DOI: 10.1182/blood-2014-03-563882  0.72
2014 Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacology & Therapeutics. 143: 323-36. PMID 24769080 DOI: 10.1016/j.pharmthera.2014.04.004  0.72
2014 Xie JH, Yamniuk AP, Borowski V, Kuhn R, Susulic V, Rex-Rabe S, Yang X, Zhou X, Zhang Y, Gillooly K, Brosius R, Ravishankar R, Waggie K, Mink K, Price L, ... ... Grant S, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. Journal of Immunology (Baltimore, Md. : 1950). 192: 4083-92. PMID 24670803 DOI: 10.4049/jimmunol.1303239  0.6
2014 Roberts JL, Booth L, Conley A, Cruickshanks N, Malkin M, Kukreja RC, Grant S, Poklepovic A, Dent P. PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biology & Therapy. 15: 758-67. PMID 24651037 DOI: 10.4161/cbt.28553  0.72
2014 Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, Orlowski RZ, Grant S. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. Plos One. 9: e89064. PMID 24594907 DOI: 10.1371/journal.pone.0089064  0.72
2014 Tavallai S, Hamed HA, Grant S, Poklepovic A, Dent P. Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biology & Therapy. 15: 578-85. PMID 24556916 DOI: 10.4161/cbt.28163  0.72
2014 Nguyen TK, Grant S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Molecular Cancer Therapeutics. 13: 662-74. PMID 24362465 DOI: 10.1158/1535-7163.MCT-13-0714  0.72
2014 Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, Das A, Fisher PB, Kukreja RC, Grant S, Poklepovic A, Dent P. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Molecular Pharmacology. 85: 408-19. PMID 24353313 DOI: 10.1124/mol.113.090043  0.72
2014 Booth L, Roberts JL, Conley A, Cruickshanks N, Ridder T, Grant S, Poklepovic A, Dent P. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biology & Therapy. 15: 305-16. PMID 24351423 DOI: 10.4161/cbt.27309  0.72
2013 Hamed HA, Das SK, Sokhi UK, Park MA, Cruickshanks N, Archer K, Ogretmen B, Grant S, Sarkar D, Fisher PB, Dent P. Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells. Cancer Biology & Therapy. 14: 1039-49. PMID 24025359 DOI: 10.4161/cbt.26110  0.72
2013 Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biology & Therapy. 14: 982-96. PMID 24025251 DOI: 10.4161/cbt.26234  0.72
2013 Bose P, Park H, Al-Khafaji J, Grant S. Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leukemia Research Reports. 2: 18-20. PMID 23977454 DOI: 10.1016/j.lrr.2013.02.001  0.72
2013 Bose P, Grant S. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leukemia Research Reports. 2: 12-14. PMID 23977453 DOI: 10.1016/j.lrr.2012.11.006  0.72
2013 Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, Dent P. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biology & Therapy. 14: 458-65. PMID 23917378 DOI: 10.4161/cbt.24424  0.72
2013 Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Molecular Pharmacology. 84: 562-71. PMID 23877009 DOI: 10.1124/mol.113.088005  0.72
2013 Liu K, Zhang D, Chojnacki J, Du Y, Fu H, Grant S, Zhang S. Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. Organic & Biomolecular Chemistry. 11: 4757-63. PMID 23784627 DOI: 10.1039/c3ob40595h  0.36
2013 Hamed HA, Yamaguchi Y, Fisher PB, Grant S, Dent P. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells. Journal of Cellular Physiology. 228: 1996-2005. PMID 23674352 DOI: 10.1002/jcp.24362  0.72
2013 Hamed HA, Yacoub A, Park MA, Archer K, Das SK, Sarkar D, Grant S, Fisher PB, Dent P. Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells. Molecular Pharmacology. 84: 171-81. PMID 23661648 DOI: 10.1124/mol.113.086553  0.72
2013 Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opinion On Investigational Drugs. 22: 723-38. PMID 23647051 DOI: 10.1517/13543784.2013.789859  0.72
2013 Dai Y, Chen S, Kmieciak M, Zhou L, Lin H, Pei XY, Grant S. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Molecular Cancer Therapeutics. 12: 878-89. PMID 23536721 DOI: 10.1158/1535-7163.MCT-12-0902  0.72
2013 Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, ... ... Grant S, et al. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1873-83. PMID 23515411 DOI: 10.1158/1078-0432.CCR-12-2926  0.72
2013 Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. Plos One. 8: e56471. PMID 23437140 DOI: 10.1371/journal.pone.0056471  0.72
2013 Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. British Journal of Haematology. 161: 43-56. PMID 23360303 DOI: 10.1111/bjh.12206  0.56
2013 Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Research. 73: 1340-51. PMID 23243017 DOI: 10.1158/0008-5472.CAN-12-1365  0.72
2013 Das SK, Bhutia SK, Azab B, Kegelman TP, Peachy L, Santhekadur PK, Dasgupta S, Dash R, Dent P, Grant S, Emdad L, Pellecchia M, Sarkar D, Fisher PB. MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Research. 73: 844-54. PMID 23233738 DOI: 10.1158/0008-5472.CAN-12-1681  0.56
2013 Dasmahapatra G, Patel H, Nguyen T, Attkisson E, Grant S. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 404-14. PMID 23204129 DOI: 10.1158/1078-0432.CCR-12-2799  0.44
2012 Bose P, Rahmani M, Grant S. Coordinate PI3K pathway and Bcl-2 family disruption in AML. Oncotarget. 3: 1499-500. PMID 23439314  0.72
2012 Bose P, Grant S. Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia? Expert Review of Hematology. 5: 475-8. PMID 23146050 DOI: 10.1586/ehm.12.43  0.72
2012 Harrison SJ, Bishton M, Bates SE, Grant S, Piekarz RL, Johnstone RW, Dai Y, Lee B, Araujo ME, Prince HM. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). Epigenomics. 4: 571-89. PMID 23130838 DOI: 10.2217/epi.12.52  0.72
2012 Grant S, Dai Y. Histone deacetylase inhibitors and rational combination therapies. Advances in Cancer Research. 116: 199-237. PMID 23088872 DOI: 10.1016/B978-0-12-394387-3.00006-9  0.72
2012 Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P. OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biology & Therapy. 13: 1501-11. PMID 22990204 DOI: 10.4161/cbt.22275  0.56
2012 Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S, Dent P. Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Molecular Pharmacology. 82: 1217-29. PMID 22989520 DOI: 10.1124/mol.112.081539  0.56
2012 Yaseen A, Chen S, Hock S, Rosato R, Dent P, Dai Y, Grant S. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Molecular Pharmacology. 82: 1030-41. PMID 22923501 DOI: 10.1124/mol.112.079624  0.72
2012 Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Research. 72: 4225-37. PMID 22693249 DOI: 10.1158/0008-5472.CAN-12-1118  0.72
2012 Bareford MD, Hamed HA, Allegood J, Cruickshanks N, Poklepovic A, Park MA, Ogretmen B, Spiegel S, Grant S, Dent P. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biology & Therapy. 13: 793-803. PMID 22673740 DOI: 10.4161/cbt.20562  0.72
2012 Tang Y, Hamed HA, Poklepovic A, Dai Y, Grant S, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Molecular Pharmacology. 82: 322-32. PMID 22596349 DOI: 10.1124/mol.112.078907  0.72
2012 Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood. 119: 6089-98. PMID 22446485 DOI: 10.1182/blood-2011-09-378141  0.72
2012 Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Molecular Cancer Therapeutics. 11: 1122-32. PMID 22411899 DOI: 10.1158/1535-7163.MCT-12-0021  0.56
2012 Tang Y, Yacoub A, Hamed HA, Poklepovic A, Tye G, Grant S, Dent P. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. Cancer Biology & Therapy. 13: 567-74. PMID 22406992 DOI: 10.4161/cbt.19771  0.72
2012 Cruickshanks N, Hamed HA, Bareford MD, Poklepovic A, Fisher PB, Grant S, Dent P. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Molecular Pharmacology. 81: 748-58. PMID 22357666 DOI: 10.1124/mol.112.077586  0.72
2012 Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, Grant S, Dent P. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biology & Therapy. 13: 224-36. PMID 22354011 DOI: 10.4161/cbt.13.4.18877  0.72
2012 Tang Y, Dai Y, Grant S, Dent P. Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biology & Therapy. 13: 379-88. PMID 22313687 DOI: 10.4161/cbt.19240  0.72
2012 Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, Dent P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Molecular Pharmacology. 81: 527-40. PMID 22219388 DOI: 10.1124/mol.111.076851  0.72
2012 Liu K, Rao W, Parikh H, Li Q, Guo TL, Grant S, Kellogg GE, Zhang S. 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization. European Journal of Medicinal Chemistry. 47: 125-37. PMID 22074985 DOI: 10.1016/j.ejmech.2011.10.031  0.72
2012 Rosato R, Hock S, Dent P, Dai Y, Grant S. LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism. Leukemia Research. 36: 491-8. PMID 22074700 DOI: 10.1016/j.leukres.2011.10.020  0.72
2012 Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA, Sarkar S, Wang XY, Hedvat M, Dmitriev IP, Curiel DT, Grant S, Dent P, Reed JC, Pellecchia M, et al. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. Journal of Cellular Physiology. 227: 2145-53. PMID 21780116 DOI: 10.1002/jcp.22947  0.72
2012 Bhutia SK, Das SK, Kegelman TP, Azab B, Dash R, Su ZZ, Wang XY, Rizzi F, Bettuzzi S, Lee SG, Dent P, Grant S, Curiel DT, Sarkar D, Fisher PB. mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. Journal of Cellular Physiology. 227: 1805-13. PMID 21732348 DOI: 10.1002/jcp.22904  0.72
2011 Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P, Grant S. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood. 118: 5189-200. PMID 21911831 DOI: 10.1182/blood-2011-02-339432  0.72
2011 Dai Y, Grant S. Methods to study cancer therapeutic drugs that target cell cycle checkpoints. Methods in Molecular Biology (Clifton, N.J.). 782: 257-304. PMID 21870298 DOI: 10.1007/978-1-61779-273-1_19  0.72
2011 Zhang Q, Sturgill JL, Kmieciak M, Szczepanek K, Derecka M, Koebel C, Graham LJ, Dai Y, Chen S, Grant S, Cichy J, Shimoda K, Gamero A, Manjili M, Bear H, et al. The role of Tyk2 in regulation of breast cancer growth. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 31: 671-7. PMID 21864028 DOI: 10.1089/jir.2011.0023  0.72
2011 Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opinion On Investigational Drugs. 20: 1397-411. PMID 21851287 DOI: 10.1517/13543784.2011.609167  0.72
2011 Dai Y, Chen S, Wang L, Pei XY, Funk VL, Kramer LB, Dent P, Grant S. Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. The Journal of Biological Chemistry. 286: 34036-50. PMID 21816815 DOI: 10.1074/jbc.M111.284216  0.72
2011 Bareford MD, Hamed HA, Tang Y, Cruickshanks N, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy. 7: 1261-2. PMID 21814046 DOI: 10.4161/auto.7.10.17029  0.72
2011 Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 10: 1686-97. PMID 21750224 DOI: 10.1158/1535-7163.MCT-10-1108  0.56
2011 Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, Tye G, Yacoub A, Dai Y, Grant S, Dent P. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death. Cancer Biology & Therapy. 12: 215-28. PMID 21642769 DOI: 10.4161/cbt.12.3.16218  0.72
2011 Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Research. 71: 4955-67. PMID 21622715 DOI: 10.1158/0008-5472.CAN-11-0898  0.72
2011 Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proceedings of the National Academy of Sciences of the United States of America. 108: 8785-90. PMID 21555592 DOI: 10.1073/pnas.1100769108  0.72
2011 Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Molecular Interventions. 11: 133-40. PMID 21540473 DOI: 10.1124/mi.11.2.11  0.72
2011 Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3219-32. PMID 21474579 DOI: 10.1158/1078-0432.CCR-11-0234  0.72
2011 Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, ... ... Grant S, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3388-97. PMID 21447728 DOI: 10.1158/1078-0432.CCR-10-2876  0.72
2011 Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. British Journal of Haematology. 153: 222-35. PMID 21375523 DOI: 10.1111/j.1365-2141.2011.08591.x  0.72
2011 Dash R, Azab B, Shen XN, Sokhi UK, Sarkar S, Su ZZ, Wang XY, Claudio PP, Dent P, Dmitriev IP, Curiel DT, Grant S, Sarkar D, Fisher PB. Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discovery Medicine. 11: 46-56. PMID 21276410  0.72
2011 Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 117: 2807-12. PMID 21239695 DOI: 10.1182/blood-2010-11-314708  0.72
2011 Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, Kramer LB, Dent P, Grant S. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood. 117: 1947-57. PMID 21148814 DOI: 10.1182/blood-2010-06-291146  0.72
2011 Park MA, Hamed HA, Mitchell C, Cruickshanks N, Dash R, Allegood J, Dmitriev IP, Tye G, Ogretmen B, Spiegel S, Yacoub A, Grant S, Curiel DT, Fisher PB, Dent P. A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels. Molecular Pharmacology. 79: 368-80. PMID 21119025 DOI: 10.1124/mol.110.069484  0.72
2008 Grant S. Cotargeting survival signaling pathways in cancer (Journal of Clinical Investigation (2008) 118, (3003-3006) DOI: 10.1172/JCI36898) Journal of Clinical Investigation. 118: 3513. DOI: 10.1172/JCI36898E1  0.72
2003 Decker RH, Levin J, Kramer LB, Dai Y, Grant S. Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis. Biochemical Pharmacology. 65: 1997-2008. PMID 12787880 DOI: 10.1016/S0006-2952(03)00149-7  0.72
2003 Wang S, Wang Z, Dent P, Grant S. Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells. Blood. 101: 3648-57. PMID 12522001 DOI: 10.1182/blood-2002-09-2739  0.72
2003 Wang S, Wang Z, Grant S. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms. Molecular Pharmacology. 63: 232-42. PMID 12488556  0.88
2002 Decker RH, Wang S, Dai Y, Dent P, Grant S. Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. Cancer Biology & Therapy. 1: 136-44. PMID 12170773  0.72
2002 Wang Z, Wang S, Dai Y, Grant S. Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L). The Journal of Pharmacology and Experimental Therapeutics. 301: 568-77. PMID 11961058  0.88
2001 Decker RH, Dai Y, Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death and Differentiation. 8: 715-24. PMID 11464216 DOI: 10.1038/sj.cdd.4400868  0.72
2001 Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Molecular Pharmacology. 60: 143-54. PMID 11408609  0.72
2001 Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, Sankala HM, Dent P, Grant S. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Research. 61: 2583-91. PMID 11289135  0.72
2000 Wang Z, Wang S, Fisher PB, Dent P, Grant S. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine. Differentiation; Research in Biological Diversity. 66: 1-13. PMID 10997587 DOI: 10.1046/j.1432-0436.2000.066001001.x  0.72
1999 Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene. 18: 7016-25. PMID 10597302 DOI: 10.1038/sj.onc.1203176  0.72
1999 Wang S, Wang Z, Boise LH, Dent P, Grant S. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia. 13: 1564-73. PMID 10516758  0.88
1999 Wang S, Wang Z, Boise L, Dent P, Grant S. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochemical and Biophysical Research Communications. 259: 67-72. PMID 10334917 DOI: 10.1006/bbrc.1999.0669  0.88
1998 Wang S, Guo CY, Castillo A, Dent P, Grant S. Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochemical Pharmacology. 56: 635-44. PMID 9783732  0.88
1998 Wang Z, Su ZZ, Fisher PB, Wang S, VanTuyle G, Grant S. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells. Experimental Cell Research. 244: 105-16. PMID 9770354 DOI: 10.1006/excr.1998.4191  0.88
1997 Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Molecular Pharmacology. 52: 1000-9. PMID 9396780  0.72
1997 Grant S. Ara-C: Cellular and molecular pharmacology Advances in Cancer Research. 72: 197-233. PMID 9338077  0.72
1997 Grant S. Modulation of ara-C induced apoptosis in leukemia by the PKC activator bryostatin 1 Frontiers in Bioscience : a Journal and Virtual Library. 2. PMID 9195893  0.72
1990 Grant S. Biochemical modulation of cytosine arabinoside Pharmacology and Therapeutics. 48: 29-44. PMID 2274576 DOI: 10.1016/0163-7258(90)90016-U  0.72
1982 Grant S, Cadman E. Modulation of 1-β-D-Arabinofuranosylcytosine Metabolism and Cytotoxicity in L1210 Cells by Fluoropyrimidine Pretreatment Cancer Research. 42: 3550-3556. PMID 6213294  0.72
Show low-probability matches.